# Kiora Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Kiora Pharmaceuticals, Inc). ## Overview Kiora Pharmaceuticals Inc. is a U.S.-based specialty clinical-stage ophthalmology company developing small-molecule therapies for retinal and inflammatory eye diseases. Its pipeline centers on KIO-301, KIO-104 and KIO-101, with the company still in development mode and reliant on external financing and partnering to advance programs toward commercialization. ## Products & services • KIO-301 vision-restoring photoswitch for retinal degeneration • KIO-104 intravitreal DHODH inhibitor for retinal inflammation • KIO-101 topical eye-drop formulation for partnering • Clinical development and regulatory advancement of ophthalmic assets • Licensing / collaboration opportunities for non-core programs - **KIO-301** (10%) — A vision-restoring small molecule photoswitch being developed for late-stage retinal degenerative diseases. - **KIO-104** (20%) — An intravitreal DHODH inhibitor in clinical development for retinal inflammatory diseases. - **KIO-101** (5%) — A topical eye-drop formulation of the KIO-104 molecule being positioned for partnership. - **Collaboration and licensing revenue** (65%) — Upfront and milestone-related revenue from partnering agreements such as the TOI license. - KIO-301 photoswitch for retinitis pigmentosa and related retinal diseases - KIO-104 intravitreal therapy for posterior non-infectious uveitis - KIO-104 development for diabetic macular edema and retinal inflammation - KIO-101 topical eye-drop version of the same molecule as KIO-104 - Partnering and licensing of pipeline assets to fund development ## Customers Kiora does not sell commercial products broadly today; its current counterparties are pharmaceutical partners, clinical investigators, and eventually ophthalmologists and specialty eye-care providers if products are approved. The company’s near-term economic model depends on licensing and collaboration partners, while the eventual end users are patients with rare or inflammatory retinal diseases treated through specialist channels. - **Pharmaceutical licensing partners** (primary) — Buy rights to KIO-301/KIO-101 or other assets to fund development and access the science. - **Clinical trial ecosystem** (primary) — Investigators, hospitals and research centers that enroll patients and generate clinical data. - **Retina specialists** (secondary) — Would prescribe KIO-301 if approved for inherited retinal degeneration. - **Uveitis and inflammatory eye disease specialists** (secondary) — Would use KIO-104 for retinal inflammatory indications if approved. - **Patients with rare ophthalmic diseases** (secondary) — End users of the therapies, especially those with limited treatment options. - Pharma partners that license assets and fund development - Clinical trial sites and investigators running ophthalmology studies - Specialist retina and uveitis physicians who would prescribe approved therapies - Patients with retinitis pigmentosa and other inherited retinal diseases - Patients with posterior non-infectious uveitis and retinal inflammation ## Geography Kiora is headquartered in the United States and its development programs are intended for major regulated markets including the U.S., Europe and other large regions. The company’s geography is therefore driven less by current sales footprint and more by where it can run clinical trials, secure regulatory approval, and sign partnering agreements. - United States is the core operating base and primary capital market - Clinical development targets the U.S. and Europe for registration studies - Partnering can extend programs outside the U.S. territory - No meaningful commercial manufacturing footprint disclosed - Geographic exposure is mainly regulatory and trial-enrollment related ## Strategy Kiora’s strategy is to advance a small number of ophthalmology assets through clinical proof-of-concept while using partnerships to reduce capital intensity. The company is also prioritizing financing flexibility, since continued development depends on equity, debt, grants and collaboration proceeds. - **Advance KIO-301 clinical development** (medium-term) — KIO-301 is the most differentiated asset and could address unmet need in inherited retinal disease. - **Enroll and generate data for KIO-104** (short-term) — Clinical validation in retinal inflammation is needed to support partnering or future commercialization. - **Partner KIO-101** (short-term) — The company has paused internal development and wants a partner to fund further work. - **Secure additional financing** (short-term) — The company needs capital to continue operations and avoid delaying or terminating programs. - Advance KIO-301 through later-stage retinal disease studies - Progress KIO-104 into Phase 2 retinal inflammation enrollment - Seek partners for KIO-101 and other non-core programs - Use collaborations to monetize assets and extend runway - Preserve cash while funding only the highest-priority studies ## Risks Kiora is a development-stage biotech with no meaningful commercial revenue, so its business depends on successful clinical outcomes, regulatory approvals and access to capital. The main risks are funding shortfalls, trial or regulatory setbacks, and the possibility that partnering terms force the company to give up economics or control over key assets. - **Financing risk** [high] — The company needs additional capital to fund operations and development, and may not obtain it on acceptable terms. - **Clinical development failure** [high] — Pipeline value depends on positive efficacy and safety data in small, specialized ophthalmic indications. - **Regulatory approval risk** [high] — Even promising data may not translate into approvable endpoints or market authorization. - **Partnering / dilution of economics** [medium] — To raise funds, Kiora may need to license assets on terms that reduce future upside. - **Going-concern and burn-rate risk** [high] — The company has a history of losses and negative cash flows, increasing sensitivity to spending changes. - Capital needs are ongoing and financing may be unavailable or dilutive - Clinical trials may fail to show efficacy or safety for KIO-301/KIO-104 - Regulatory approval is uncertain and can delay commercialization - Partnering may require surrendering rights or future revenue streams - As a pre-commercial biotech, losses and negative cash flow are expected ## Accounting Kiora’s accounting is dominated by collaboration revenue recognition, R&D expense timing, and going-concern judgments. Because the company is pre-commercial, small changes in partnership accounting, clinical trial accruals, or fair-value estimates can materially affect reported results. - **Collaboration revenue recognition** — Revenue timing can be lumpy and driven by contract terms rather than product sales - **Clinical trial accruals and R&D estimates** — Quarterly operating expense volatility - **Going-concern assessment** — Material for liquidity and valuation analysis - **Stock-based compensation** — Affects operating loss and non-cash expense - Upfront license payments may be recognized as collaboration revenue - R&D accruals depend on clinical trial timing and vendor estimates - Going-concern disclosures reflect runway and financing uncertainty - Stock-based compensation can be material for a small biotech - Any future milestones or royalties will affect revenue timing --- *Last updated: 2026-04-28T20:19:35.412044+00:00*